Published in Gene Therapy Weekly, July 29th, 2004
The new company is backed by private investors and QIAGEN will retain a minority stake of 16%. The new company, to be named Operon Biotechnologies Inc., expects to continue to expand the leadership position QIAGEN has built in this market. QIAGEN will retain all rights and activities in its leading siRNA business including ownership of QIAGEN's proprietary TOM-amidite chemistry.
Pursuant to the terms of the agreements, QIAGEN will retain a minority...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.